Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)

Affiliations

¹ Royal National ENT Hospital, University College Hospitals London, Division of Infection and Immunity, University College London, London, United Kingdom. Electronic address: g.scadding@ucl.ac.uk.
² Allergy and Clinical Immunology, Imperial College, London, United Kingdom.

Editorial

Glenis K Scadding et al. J Allergy Clin Immunol. 2022 Mar.

. 2022 Mar;149(3):895-897.

doi: 10.1016/j.jaci.2021.10.029. Epub 2021 Nov 6.

¹ Royal National ENT Hospital, University College Hospitals London, Division of Infection and Immunity, University College London, London, United Kingdom. Electronic address: g.scadding@ucl.ac.uk.
² Allergy and Clinical Immunology, Imperial College, London, United Kingdom.

No abstract available

Keywords: CRSwNP; Chronic rhinosinusitis with nasal polyps; JAK-selective inhibitors; SNOT-22; biologics; omalizumab.

Comment on

Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE, Ow RA, Zhao R, Howard M, Wong K, Islam L, Ligueros-Saylan M, Omachi TA, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2022 Mar;149(3):957-965.e3. doi: 10.1016/j.jaci.2021.07.045. Epub 2021 Sep 14. J Allergy Clin Immunol. 2022. PMID: 34530020 Clinical Trial.